The Hadassah Medical Center has partnered with a leading research company to test the efficacy of a rice bran nutrient as supportive therapy for HIV/AIDS patients.
The randomized, placebo-controlled, clinical trial will include 140 patients, some of whom are already taking anti-retroviral drugs. It will address an important topic in AIDS medicine: the value of nutrients and specifically, RiSolubles, a derivative of stabilized rice bran, in boosting a patient’s immune status beyond what is achieved with anti-retroviral drugs. The study is being conducted in conjunction with NutraCea, a leader in stabilized rice bran nutrient research and dietary supplement development. Co-Principal Investigators from Hadassah are Prof. Allon Moses, Chairman of Hadassah’s Department of Clinical Microbiology and Infectious Disease, and Prof. Shlomo Maayan, Director of Hadassah’s AIDS Center.

Hadassah’s physicians wanted to conduct a study of this nature based on years of anecdotal reports and more recent written reports from feeding programs in Malawi and Central America. The reports suggest that, thanks to particular nutrition regimens, people with HIV/AIDS were gaining weight, feeling more energetic, and enjoying a better quality of life.

“We are very pleased to announce that our first human trial is underway at a highly respected medical institution, renowned for its research in HIV/AIDS,” commented Brad Edson, President and Chief Executive Officer of NutraCea. He added: “We hope to demonstrate a new, novel nutritional approach for millions of people around the world who are suffering from HIV/AIDS.”